These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 25447941

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of early crush on aging wild type and Connexin 32 knockout mice: Evidence for a neuroprotective state in CMT1X mouse nerve.
    Peinado A, Asche-Godin SL, Freidin MM, Abrams CK.
    J Peripher Nerv Syst; 2021 Jun; 26(2):167-176. PubMed ID: 33624350
    [Abstract] [Full Text] [Related]

  • 3. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease.
    Sargiannidou I, Kagiava A, Bashiardes S, Richter J, Christodoulou C, Scherer SS, Kleopa KA.
    Ann Neurol; 2015 Aug; 78(2):303-16. PubMed ID: 26010264
    [Abstract] [Full Text] [Related]

  • 4. Intrathecal gene therapy in mouse models expressing CMT1X mutations.
    Kagiava A, Karaiskos C, Richter J, Tryfonos C, Lapathitis G, Sargiannidou I, Christodoulou C, Kleopa KA.
    Hum Mol Genet; 2018 Apr 15; 27(8):1460-1473. PubMed ID: 29462293
    [Abstract] [Full Text] [Related]

  • 5. Altered gene expression in Schwann cells of connexin32 knockout animals.
    Nicholson SM, Gomès D, de Néchaud B, Bruzzone R.
    J Neurosci Res; 2001 Oct 01; 66(1):23-36. PubMed ID: 11598999
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Molecular genetics of X-linked Charcot-Marie-Tooth disease.
    Kleopa KA, Scherer SS.
    Neuromolecular Med; 2006 Oct 01; 8(1-2):107-22. PubMed ID: 16775370
    [Abstract] [Full Text] [Related]

  • 8. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.
    Kagiava A, Karaiskos C, Richter J, Tryfonos C, Jennings MJ, Heslegrave AJ, Sargiannidou I, Stavrou M, Zetterberg H, Reilly MM, Christodoulou C, Horvath R, Kleopa KA.
    Gene Ther; 2021 Nov 01; 28(10-11):659-675. PubMed ID: 33692503
    [Abstract] [Full Text] [Related]

  • 9. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?
    Kleopa KA, Abrams CK, Scherer SS.
    Brain Res; 2012 Dec 03; 1487():198-205. PubMed ID: 22771394
    [Abstract] [Full Text] [Related]

  • 10. Connexins, gap junctions and peripheral neuropathy.
    Kleopa KA, Sargiannidou I.
    Neurosci Lett; 2015 Jun 02; 596():27-32. PubMed ID: 25449862
    [Abstract] [Full Text] [Related]

  • 11. Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X.
    Kyriakoudi S, Sargiannidou I, Kagiava A, Olympiou M, Kleopa KA.
    Hum Mol Genet; 2017 May 01; 26(9):1622-1633. PubMed ID: 28334782
    [Abstract] [Full Text] [Related]

  • 12. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.
    Kagiava A, Richter J, Tryfonos C, Karaiskos C, Heslegrave AJ, Sargiannidou I, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Kleopa KA.
    Hum Mol Genet; 2019 Nov 01; 28(21):3528-3542. PubMed ID: 31411673
    [Abstract] [Full Text] [Related]

  • 13. The effects of a dominant connexin32 mutant in myelinating Schwann cells.
    Jeng LJ, Balice-Gordon RJ, Messing A, Fischbeck KH, Scherer SS.
    Mol Cell Neurosci; 2006 Jul 01; 32(3):283-98. PubMed ID: 16790356
    [Abstract] [Full Text] [Related]

  • 14. Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease.
    Olympiou M, Sargiannidou I, Markoullis K, Karaiskos C, Kagiava A, Kyriakoudi S, Abrams CK, Kleopa KA.
    Acta Neuropathol Commun; 2016 Sep 01; 4(1):95. PubMed ID: 27585976
    [Abstract] [Full Text] [Related]

  • 15. Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy.
    Vavlitou N, Sargiannidou I, Markoullis K, Kyriacou K, Scherer SS, Kleopa KA.
    J Neuropathol Exp Neurol; 2010 Sep 01; 69(9):945-58. PubMed ID: 20720503
    [Abstract] [Full Text] [Related]

  • 16. Two new mouse models of Gjb1-associated Charcot-Marie-Tooth disease type 1X.
    Tadenev ALD, Hatton CL, Pattavina B, Mullins T, Schneider R, Bogdanik LP, Burgess RW.
    J Peripher Nerv Syst; 2023 Sep 01; 28(3):317-328. PubMed ID: 37551045
    [Abstract] [Full Text] [Related]

  • 17. Pathogenesis of X-linked Charcot-Marie-Tooth disease: differential effects of two mutations in connexin 32.
    Abrams CK, Freidin M, Bukauskas F, Dobrenis K, Bargiello TA, Verselis VK, Bennett MV, Chen L, Sahenk Z.
    J Neurosci; 2003 Nov 19; 23(33):10548-58. PubMed ID: 14627639
    [Abstract] [Full Text] [Related]

  • 18. CSF-1-activated macrophages are target-directed and essential mediators of Schwann cell dedifferentiation and dysfunction in Cx32-deficient mice.
    Groh J, Klein I, Hollmann C, Wettmarshausen J, Klein D, Martini R.
    Glia; 2015 Jun 19; 63(6):977-86. PubMed ID: 25628221
    [Abstract] [Full Text] [Related]

  • 19. X-linked Charcot-Marie-Tooth disease.
    Scherer SS, Kleopa KA.
    J Peripher Nerv Syst; 2012 Dec 19; 17 Suppl 3(0 3):9-13. PubMed ID: 23279425
    [Abstract] [Full Text] [Related]

  • 20. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ.
    Acta Neurol Scand Suppl; 2012 Dec 19; (193):iv-22. PubMed ID: 23106488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.